Cytosorbents Corp. (CTSO) Dividend History

Company News

• CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update

  CytoSorbents reported a 3% decrease in Q1 2025 revenue, but improved operating loss and net loss. The company is making progress with its DrugSorb-ATR device, which is under review by the FDA and Health Canada.

  Benzinga
• CytoSorbents Provides Regulatory Update for DrugSorb-ATR

  CytoSorbents Corporation received a denial letter from the FDA regarding its De Novo Request for DrugSorb-ATR, a device designed to reduce bleeding in CABG patients on the antiplatelet drug Brilinta. The company plans to continue working with the FDA to resolve the remaining issues and obtain regulatory approval.

  Benzinga
• Health Care Equipment Supplier CytoSorbents Shares Dip Despite Projected Revenue Growth

  CytoSorbents reported strong Q4 2024 preliminary results, with product revenue growth of 22-25% and gross margin improvement to 70%. However, the company's shares dipped despite the positive outlook, as it prepares to enter the North American market with its DrugSorb-ATR product pending regulatory approvals.

  Benzinga
• CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue

  CytoSorbents Corporation reported strong preliminary Q4 2024 financial results, with product revenue growth estimated at 22-25% year-over-year and gross margin improving to around 70%. The company also provided updates on its regulatory progress for DrugSorb-ATR, an investigational device to reduce perioperative bleeding in CABG surgery patients.

  GlobeNewswire Inc.
• Why CytoSorbents (CTSO) Stock Is Trading Higher - CytoSorbents (NASDAQ:CTSO) - Benzinga

  CytoSorbents shares are trading 21% higher after the company entered into a new $20 million credit facility with Avenue Capital Group to support its CytoSorb® franchise and aid in FDA and Health Canada applications for DrugSorb™-ATR.

  Benzinga